image
Healthcare - Medical - Care Facilities - NYSE - US
$ 78.5
0.319 %
$ 13.6 B
Market Cap
36.18
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one SOLV stock under the worst case scenario is HIDDEN Compared to the current market price of 78.5 USD, Solventum Corporation is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one SOLV stock under the base case scenario is HIDDEN Compared to the current market price of 78.5 USD, Solventum Corporation is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one SOLV stock under the best case scenario is HIDDEN Compared to the current market price of 78.5 USD, Solventum Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SOLV

image
$85.0$85.0$80.0$80.0$75.0$75.0$70.0$70.0$65.0$65.0$60.0$60.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
8.25 B REVENUE
0.70%
1.04 B OPERATING INCOME
-38.77%
479 M NET INCOME
-64.41%
1.18 B OPERATING CASH FLOW
-38.12%
-380 M INVESTING CASH FLOW
-65.22%
-240 M FINANCING CASH FLOW
84.54%
2.07 B REVENUE
-0.19%
152 M OPERATING INCOME
11.76%
137 M NET INCOME
356.67%
29 M OPERATING CASH FLOW
-86.76%
-114 M INVESTING CASH FLOW
10.24%
-139 M FINANCING CASH FLOW
-33.65%
Balance Sheet Solventum Corporation
image
Current Assets 3.25 B
Cash & Short-Term Investments 762 M
Receivables 1.23 B
Other Current Assets 1.26 B
Non-Current Assets 11.2 B
Long-Term Investments 0
PP&E 1.62 B
Other Non-Current Assets 9.59 B
5.27 %8.50 %8.70 %11.22 %66.31 %Total Assets$14.5b
Current Liabilities 2.7 B
Accounts Payable 618 M
Short-Term Debt 200 M
Other Current Liabilities 1.88 B
Non-Current Liabilities 8.8 B
Long-Term Debt 7.81 B
Other Non-Current Liabilities 985 M
5.37 %16.39 %67.92 %8.57 %Total Liabilities$11.5b
EFFICIENCY
Earnings Waterfall Solventum Corporation
image
Revenue 8.25 B
Cost Of Revenue 3.66 B
Gross Profit 4.59 B
Operating Expenses 3.56 B
Operating Income 1.04 B
Other Expenses 557 M
Net Income 479 M
9b9b8b8b7b7b6b6b5b5b4b4b3b3b2b2b1b1b008b(4b)5b(4b)1b(557m)479mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
55.65% GROSS MARGIN
55.65%
12.55% OPERATING MARGIN
12.55%
5.80% NET MARGIN
5.80%
16.19% ROE
16.19%
3.31% ROA
3.31%
6.85% ROIC
6.85%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Solventum Corporation
image
2b2b2b2b2b2b1b1b1b1b1b1b800m800m600m600m400m400m200m200m0020212021Jul '21Jul '2120222022Jul '22Jul '2220232023Jul '23Jul '2320242024Jul '24Jul '2420252025
Net Income 479 M
Depreciation & Amortization 555 M
Capital Expenditures -380 M
Stock-Based Compensation 112 M
Change in Working Capital 160 M
Others 17 M
Free Cash Flow 805 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Solventum Corporation
image
Wall Street analysts predict an average 1-year price target for SOLV of $72.5 , with forecasts ranging from a low of $55 to a high of $82 .
SOLV Lowest Price Target Wall Street Target
55 USD -29.94%
SOLV Average Price Target Wall Street Target
72.5 USD -7.64%
SOLV Highest Price Target Wall Street Target
82 USD 4.46%
Price
Max Price Target
Min Price Target
Average Price Target
85858080757570706565606055555050Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Solventum Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Solventum Named a Best Company to Work for by U.S. News & World Report Recognized among the top 25 percent of companies in healthcare and research, and top 25 percent of companies in the Midwest in just 14 months as a new company Award highlights success in phase one of Solventum's  three-phased Transformation Plan ST. PAUL, Minn. prnewswire.com - 3 weeks ago
Solventum to Participate in the 2025 Goldman Sachs Health Care Conference ST. PAUL, Minn. , June 3, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today its executives will participate in a fireside chat at the Goldman Sachs 46th Annual Global Health Care Conference on Tuesday, June 10, 2025, beginning at approximately 4:00 p.m. prnewswire.com - 1 month ago
SOLV's Strong Q1 Signals Turnaround: Is the Stock Worth Betting Now? Solventum beats Q1 estimates, raises guidance, and powers ahead with transformation despite looming tariff headwinds. zacks.com - 1 month ago
Solventum (SOLV) Just Overtook the 200-Day Moving Average Solventum (SOLV) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, SOLV broke through the 200-day moving average, which suggests a long-term bullish trend. zacks.com - 1 month ago
Solventum Corporation (SOLV) Q1 2025 Earnings Call Transcript Solventum Corporation (NYSE:SOLV ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Amy Wakeham - Senior Vice President of Investor Relations & External Finance Communications Bryan Hanson - Chief Executive Officer Wayde McMillan - Chief Financial Officer Conference Call Participants Patrick Wood - Morgan Stanley Frederick Wise - Stifel, Nicolaus & Company, Inc. Jason Bednar - Piper Sandler & Co. David Roman - Goldman Sachs Group, Inc. Travis Steed - Bank of America Steven Valiquette - Mizuho Securities Operator Good afternoon. My name is Amy [ph] and I will be your conference call operator for today. seekingalpha.com - 1 month ago
Solventum Corporation: Cheap, With Caveats Solventum Corporation's stock has dropped 20% since February despite beating earnings and revenue expectations in its last two quarterly reports. SOLV operates in four divisions: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration, with a market cap of $11.5 billion. The company recently announced the sale of its Purification and Filtration business to Thermo Fisher at what seems a more than solid price. seekingalpha.com - 2 months ago
Solventum Stock Gains on Q1 Earnings & Revenue Beat, Margins Decline SOLV's first-quarter earnings showcase strong segmental performance. However, declining margins raise concerns. zacks.com - 2 months ago
Solventum (SOLV) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates Although the revenue and EPS for Solventum (SOLV) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 2 months ago
Solventum (SOLV) Tops Q1 Earnings and Revenue Estimates Solventum (SOLV) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.19 per share. This compares to earnings of $2.08 per share a year ago. zacks.com - 2 months ago
Solventum beats first-quarter profit estimates on strong surgical product sales 3M spin-off Solventum beat analysts' estimate for first-quarter profit on Thursday, helped by higher sales of its wound care, sterilization products. reuters.com - 2 months ago
Solventum to Participate in the 2025 BofA Securities Health Care Conference ST. PAUL, Minn. , May 8, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today its executives will participate in a fireside chat at the 2025 BofA Securities Health Care Conference on Tuesday, May 13, 2025, beginning at approximately 2:20 p.m. prnewswire.com - 2 months ago
Solventum Reports First Quarter 2025 Financial Results Reported sales increased 2.6%; organic sales increased 4.3% Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5% ST. PAUL, Minn. prnewswire.com - 2 months ago
8. Profile Summary

Solventum Corporation SOLV

image
COUNTRY US
INDUSTRY Medical - Care Facilities
MARKET CAP $ 13.6 B
Dividend Yield 0.00%
Description Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.
Contact 3M Center, Maplewood, MN, 55144 https://www.solventum.com
IPO Date April 1, 2024
Employees 22000
Officers Mr. Bryan C. Hanson Chief Executive Officer & Director Ms. Amy Wakeham Senior Vice President of Investor Relations & External Finance Communications Mr. Wayde D. McMillan Chief Financial Officer Ms. Tammy L. Gomez Chief Human Resources Officer Mr. J. Christopher Barry Executive Vice President & Group President of Medical Surgical Ms. Marcela A. Kirberger Chief Legal Affairs Officer & Corporate Secretary Ms. Mary T. Wilcox Senior Vice President, Corporate Controller & Chief Accounting Officer Ms. Rachel H. Ellingson Chief Strategy & Corporate Development Officer Ms. Amy Landucci Chief Information & Digital Officer Ms. Kate Dobbs Chief Communications & Brand Officer